A Phase 2 interventional study of Recombinant human growth hormone (r-hGH) in Hypochondroplasia, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Mucopolysaccharidosis IV with a site in France — 8 open to participants now, 8 under way, 1 of them phase 3. Mucopolysaccharidosis IV · France.
Among the 19 studies in Mucopolysaccharidosis IV with a site in France, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 2, and was the 2nd registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →8 of the 19 studies in Mucopolysaccharidosis IV with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 4–18
University Hospital, Angers · Sites in France
Ages 18+
QED Therapeutics, a BridgeBio company · Sites in France, United States, Australia and 7 more countries
Ages 30 mo–16 yrs
Innoskel · Sites in France, Spain
Ages up to 12
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 61 across 56 interventional studies indexed under Mucopolysaccharidosis IV.
Median enrollment 135 across the 11 interventional studies, 236 across the 8 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 1 study filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
4 of the studies in Mucopolysaccharidosis IV with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT06036693Institut National de la Santé Et de la Recherche Médicale, FranceMPS (RaDiCo Cohort) (RaDiCo-MPS) | 2026-12 |
| NCT05408715InnoskelA Natural History Study in Children With a Type II Collagen Disorder With Short Stature | 2026-12-31 |
| NCT06675097University Hospital, AngersAssessment of the Impact of Intestinal Gas Emission Quality on the Postoperative Course After Abdominal Surgery | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Mucopolysaccharidosis IV with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for each study prolongation:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Recombinant human growth hormone (r-hGH)
Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
Also known as: Saizen®, Somatropin
Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
Time frame: Baseline (Month 0), Year 3
Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 4
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
Time frame: Year 4
Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Change From Baseline in Height of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Body proportion was measured in terms of height. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Change From Baseline in Upper Segment (Superior) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Body proportion was measured in terms of upper segment for standing and sitting position. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Change From Baseline in Weight of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
The body weight was measured on a certified and calibrated hospital scale. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Change From Baseline in Body Mass Index (BMI) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9.5 Years
Body proportion measured as BMI. It was calculated according to the formula BMI = Weight (kilogram)/Height square (meter square). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Change From Baseline in Bone Mineral Density (BMD) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Body composition measured as BMD. It was examined at the lumbar spine (L1-L4) and determined annually by dual-energy X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Change From Baseline in Percent Body Fat Mass of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Body composition measured as percentage of body fat mass. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Change From Baseline in Lean Body Mass (LBM) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) up to 9 Years
Body composition measured as LBM. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
Time frame: Baseline (Month 0), Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 9 (only for male)
Growth (Height) Velocity of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Growth velocity was calculated in terms of height velocity. It corresponded to a difference in height between current and baseline values divided by the time interval between both evaluations. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Head Circumference Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Body proportion was measured in terms of head circumference with a tape measure. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male) and 9.5 (only for male)
Osteocalcin Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
Osteocalcin as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)
C-terminal Telopeptide (CTX) Values of Recombinant Human Growth Hormone (r-hGH) Treated Subjects With Hypochondroplasia (HCH) From Year 1 up to 9.5 Years
CTX (Blood) as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
Time frame: Year 1, 2, 3, 4, 5, 6, 7, 8 (both male and female); 8.5 (only for female), 9 (only for male), 9.5 (only for male)
Number of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation
Genetic analysis was performed to record FGFR3 gene mutation. Genomic DNA was extracted from lymphocytes of collected blood samples using standard procedures. A set of intronic primers was designed based on the genomic sequence of the human FGFR3 gene and used to amplify exons 2-19. Number of subjects with FGFR3 mutation were reported.
Time frame: Baseline up to 3 years
Number of Subjects With Adverse Event (AE) and Serious Adverse Event (SAE)
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose.
Time frame: Baseline up to 9.5 years
The study was conducted between March 21, 2006 and January 17, 2017.
| Milestone | r-hGH (Saizen®) |
|---|---|
| Started | 19 |
| Completed | 16 |
| Not completed | 3 |
| Withdrew: Withdrew prematurely | 2 |
| Withdrew: Other | 1 |
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
| Standard Deviation Score (SDS) | r-hGH (Saizen®) |
|---|---|
| Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3 | 1.39 ± 0.9 |
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
| Standard Deviation Score (SDS) | r-hGH (Saizen®) |
|---|---|
| Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 4 | 25.6 ± 3.5 |
Height was calculated in standardized units expressed as the standard deviation score (SDS), where SDS = (x - m)/sigma, in which x represents the height variable measured by sex and age, and m and sigma are the statistical parameters (mean and standard deviation) for the Sempe reference population. The reference population was the historical cohort consisting of non-treated subjects with Hypochondroplasia (HCH). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a participant's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated smaller height for the respective age/gender.
| Standard Deviation Score (SDS) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | -1.82 (-3.4 to -1.4) |
| Male: Year 2 | -1.51 (-3.4 to -1.1) |
| Male: Year 3 | -1.30 (-3.7 to -1.0) |
| Male: Year 4 | -1.49 (-3.7 to -1.0) |
| Male: Year 5 | -1.51 (-3.5 to -1.0) |
| Male: Year 6 | -2.88 (-3.8 to -2.0) |
| Male: Year 7 | -3.9 (-3.9 to -3.9) |
| Male: Year 8 | -3.90 (-3.9 to -3.9) |
| Male: Year 9 | -5.0 (-5.0 to -5.0) |
| Male: Year 9.5 | -5.6 (-5.6 to -5.6) |
| Female: Year 1 | -2.69 (-5.3 to -0.6) |
| Female: Year 2 | -2.52 (-5.8 to -0.7) |
| Female: Year 3 | -2.61 (-6.0 to -0.6) |
| Female: Year 4 | -1.09 (-1.5 to -0.9) |
| Female: Year 5 | -1.63 (-1.9 to -1.4) |
| Female: Year 6 | -2.51 (-3.4 to -1.6) |
| Female: Year 7 | -2.74 (-3.7 to -1.8) |
| Female: Year 8 | -2.8 (-2.8 to -2.8) |
| Female: Year 8.5 | -3.1 (-3.1 to -3.1) |
Body proportion was measured in terms of height. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Centimeter (cm) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 8.10 ± 1.867 |
| Male: Year 2 | 14.59 ± 2.527 |
| Male: Year 3 | 20.00 ± 3.398 |
| Male: Year 4 | 23.74 ± 4.136 |
| Male: Year 5 | 29.06 ± 4.809 |
| Male: Year 6 | 31.35 ± 8.556 |
| Male: Year 7 | 28.40 ± NA |
| Male: Year 8 | 34.73 ± NA |
| Male: Year 9 | 37.98 ± NA |
| Male: Year 9.5 | 38.37 ± NA |
| Female: Year 1 | 7.72 ± 1.642 |
| Female: Year 2 | 13.76 ± 3.505 |
| Female: Year 3 | 17.95 ± 5.189 |
| Female: Year 4 | 26.96 ± 2.394 |
| Female: Year 5 | 30.08 ± 3.791 |
| Female: Year 6 | 32.50 ± 0.566 |
| Female: Year 7 | 36.92 ± 0.024 |
| Female: Year 8 | 39.47 ± NA |
| Female: Year 8.5 | 40.87 ± NA |
Body proportion was measured in terms of upper segment for standing and sitting position. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Centimeter (cm) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 3.80 ± 1.656 |
| Male: Year 2 | 7.96 ± 4.172 |
| Male: Year 3 | 8.93 ± 9.504 |
| Male: Year 4 | 16.50 ± NA |
| Male: Year 5 | 16.98 ± 2.161 |
| Male: Year 6 | 17.05 ± 6.576 |
| Male: Year 9 | 18.70 ± NA |
| Male: Year 9.5 | 27.80 ± NA |
| Female: Year 1 | 4.19 ± 0.909 |
| Female: Year 2 | 9.21 ± 2.450 |
| Female: Year 3 | 13.41 ± 1.978 |
| Female: Year 4 | 15.70 ± 2.546 |
| Female: Year 5 | 15.20 ± 0.849 |
| Female: Year 6 | 18.35 ± 0.354 |
| Female: Year 7 | 21.90 ± 0.707 |
| Female: Year 8 | 24.40 ± NA |
The body weight was measured on a certified and calibrated hospital scale. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Kilogram (kg) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 4.58 ± 2.715 |
| Male: Year 2 | 9.95 ± 4.577 |
| Male: Year 3 | 15.18 ± 6.259 |
| Male: Year 4 | 14.25 ± 3.948 |
| Male: Year 5 | 20.00 ± 7.024 |
| Male: Year 6 | 25.00 ± 11.314 |
| Male: Year 7 | 19.00 ± NA |
| Male: Year 8 | 23.00 ± NA |
| Male: Year 9 | 28.90 ± NA |
| Male: Year 9.5 | 31.00 ± NA |
| Female: Year 1 | 4.72 ± 1.537 |
| Female: Year 2 | 9.85 ± 3.946 |
| Female: Year 3 | 14.37 ± 4.905 |
| Female: Year 4 | 14.70 ± 5.510 |
| Female: Year 5 | 14.93 ± 3.101 |
| Female: Year 6 | 21.25 ± 1.061 |
| Female: Year 7 | 26.25 ± 1.061 |
| Female: Year 8 | 35.20 ± NA |
| Female: Year 8.5 | 38.00 ± NA |
Body proportion measured as BMI. It was calculated according to the formula BMI = Weight (kilogram)/Height square (meter square). Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Kilogram per meter square (kg/m^2) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 0.43 ± 0.579 |
| Male: Year 2 | 1.56 ± 0.968 |
| Male: Year 3 | 2.71 ± 1.302 |
| Male: Year 4 | 2.21 ± 1.147 |
| Male: Year 5 | 3.60 ± 2.240 |
| Male: Year 6 | 5.02 ± 1.039 |
| Male: Year 7 | 4.43 ± NA |
| Male: Year 8 | 4.57 ± NA |
| Male: Year 9 | 6.63 ± NA |
| Male: Year 9.5 | 7.60 ± NA |
| Female: Year 1 | 0.85 ± 1.112 |
| Female: Year 2 | 2.12 ± 1.978 |
| Female: Year 3 | 3.49 ± 2.341 |
| Female: Year 4 | 2.12 ± 1.778 |
| Female: Year 5 | 2.36 ± 2.207 |
| Female: Year 6 | 4.90 ± 0.634 |
| Female: Year 7 | 6.19 ± 0.408 |
| Female: Year 8 | 9.83 ± NA |
| Female: Year 8.5 | 10.71 ± NA |
Body composition measured as BMD. It was examined at the lumbar spine (L1-L4) and determined annually by dual-energy X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
| Gram per square centimeter (g/cm^2) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 0.05 ± 0.050 |
| Male: Year 2 | 0.11 ± 0.063 |
| Male: Year 3 | 0.14 ± 0.059 |
| Male: Year 4 | 0.11 ± 0.054 |
| Male: Year 5 | 0.15 ± 0.064 |
| Male: Year 6 | 0.18 ± 0.182 |
| Male: Year 8 | 0.06 ± NA |
| Male: Year 9 | 0.12 ± NA |
| Female: Year 1 | 0.05 ± 0.042 |
| Female: Year 2 | 0.09 ± 0.053 |
| Female: Year 3 | 0.15 ± 0.089 |
| Female: Year 4 | 0.22 ± 0.104 |
| Female: Year 5 | 0.17 ± 0.006 |
| Female: Year 6 | 0.19 ± 0.004 |
| Female: Year 7 | 0.26 ± 0.028 |
| Female: Year 8 | 0.40 ± NA |
Body composition measured as percentage of body fat mass. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
| Percentage (%) of body fat mass | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | -4.54 ± 2.049 |
| Male: Year 2 | -4.49 ± 3.007 |
| Male: Year 3 | -2.80 ± 3.967 |
| Male: Year 4 | -3.40 ± 4.493 |
| Male: Year 5 | -2.33 ± 5.708 |
| Male: Year 6 | -0.65 ± 11.384 |
| Male: Year 8 | 5.70 ± NA |
| Male: Year 9 | 1.90 ± NA |
| Female: Year 1 | -3.50 ± 3.185 |
| Female: Year 2 | -2.27 ± 4.441 |
| Female: Year 3 | -2.74 ± 5.227 |
| Female: Year 4 | -1.40 ± 3.536 |
| Female: Year 5 | -2.50 ± 1.131 |
| Female: Year 6 | 0.05 ± 6.576 |
| Female: Year 7 | -0.50 ± 5.798 |
Body composition measured as LBM. It was measured by Dual X-ray absorptiometry. Data was reported by gender. Male subjects were analyzed till 9 years and female subjects were analyzed till 8 years.
| Gram (g) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 4966.46 ± 2670.694 |
| Male: Year 2 | 9134.35 ± 4747.742 |
| Male: Year 3 | 11182.24 ± 4126.876 |
| Male: Year 4 | 11599.80 ± 4560.877 |
| Male: Year 5 | 15729.38 ± 6102.608 |
| Male: Year 6 | 20667.65 ± 14985.50 |
| Male: Year 8 | 15773.80 ± NA |
| Male: Year 9 | 21713.10 ± NA |
| Female: Year 1 | 4384.54 ± 1400.497 |
| Female: Year 2 | 6720.74 ± 2597.295 |
| Female: Year 3 | 9229.21 ± 2740.883 |
| Female: Year 4 | 11791.85 ± 1173.161 |
| Female: Year 5 | 12989.50 ± 83.439 |
| Female: Year 6 | 14860.75 ± 2140.483 |
| Female: Year 7 | 18111.60 ± 1239.275 |
Growth velocity was calculated in terms of height velocity. It corresponded to a difference in height between current and baseline values divided by the time interval between both evaluations. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Centimeter per year (cm/year) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 8.21 ± 2.001 |
| Male: Year 2 | 7.26 ± 1.292 |
| Male: Year 3 | 6.55 ± 1.104 |
| Male: Year 4 | 5.88 ± 1.060 |
| Male: Year 5 | 5.77 ± 0.968 |
| Male: Year 6 | 4.98 ± 1.313 |
| Male: Year 7 | 3.92 ± NA |
| Male: Year 8 | 4.25 ± NA |
| Male: Year 9 | 4.11 ± NA |
| Male: Year 9.5 | 3.94 ± NA |
| Female: Year 1 | 7.53 ± 1.460 |
| Female: Year 2 | 6.64 ± 1.713 |
| Female: Year 3 | 5.86 ± 1.677 |
| Female: Year 4 | 6.57 ± 0.572 |
| Female: Year 5 | 5.89 ± 0.787 |
| Female: Year 6 | 5.13 ± 0.006 |
| Female: Year 7 | 5.06 ± 0.120 |
| Female: Year 8 | 4.69 ± NA |
| Female: Year 8.5 | 4.54 ± NA |
Body proportion was measured in terms of head circumference with a tape measure. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Centimeter (cm) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 56.11 ± 1.268 |
| Male: Year 2 | 56.53 ± 1.359 |
| Male: Year 3 | 57.38 ± 1.734 |
| Male: Year 4 | 57.33 ± 2.021 |
| Male: Year 5 | 56.88 ± 1.887 |
| Male: Year 6 | 55.50 ± NA |
| Male: Year 7 | 57.00 ± NA |
| Male: Year 9 | 57.50 ± NA |
| Male: Year 9.5 | 58.00 ± NA |
| Female: Year 1 | 55.20 ± 2.379 |
| Female: Year 2 | 56.06 ± 1.841 |
| Female: Year 3 | 56.23 ± 2.453 |
| Female: Year 4 | 58.00 ± NA |
| Female: Year 5 | 54.33 ± 3.512 |
| Female: Year 6 | 57.25 ± 1.768 |
| Female: Year 7 | 56.75 ± 1.061 |
| Female: Year 8 | 59.00 ± NA |
Osteocalcin as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| Nanogram per milliliter (ng/mL) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 123.06 ± 55.820 |
| Male: Year 2 | 145.00 ± 35.705 |
| Male: Year 3 | 130.13 ± 36.408 |
| Male: Year 4 | 101.00 ± 34.708 |
| Male: Year 5 | 139.25 ± 76.908 |
| Male: Year 6 | 75.50 ± 47.376 |
| Male: Year 7 | 113.00 ± NA |
| Male: Year 8 | 117.00 ± NA |
| Male: Year 9 | 159.80 ± NA |
| Male: Year 9.5 | 131.60 ± NA |
| Female: Year 1 | 148.00 ± 46.183 |
| Female: Year 2 | 122.82 ± 46.531 |
| Female: Year 3 | 94.73 ± 33.344 |
| Female: Year 4 | 102.00 ± 26.268 |
| Female: Year 5 | 84.33 ± 22.591 |
| Female: Year 6 | 106.00 ± 22.627 |
| Female: Year 7 | 77.50 ± 19.092 |
| Female: Year 8 | 73.70 ± NA |
CTX (Blood) as bone marker was analyzed with the Immunology system Elecsys. Data was reported by gender. Male subjects were analyzed till 9.5 years and female subjects were analyzed till 8.5 years.
| picomole per liter (pmol/L) | r-hGH (Saizen®) |
|---|---|
| Male: Year 1 | 15784.17 ± 1426.214 |
| Male: Year 2 | 16304.13 ± 2537.725 |
| Male: Year 3 | 15703.50 ± 3249.336 |
| Male: Year 4 | 15868.25 ± 4485.621 |
| Male: Year 5 | 17088.75 ± 5208.676 |
| Male: Year 6 | 12361.00 ± 4000.810 |
| Male: Year 7 | 13795.00 ± NA |
| Male: Year 8 | 15345.00 ± NA |
| Male: Year 9 | 15655.00 ± NA |
| Male: Year 9.5 | 17205.00 ± NA |
| Female: Year 1 | 16008.00 ± 2725.874 |
| Female: Year 2 | 15183.09 ± 4371.058 |
| Female: Year 3 | 12595.18 ± 3172.529 |
| Female: Year 4 | 13911.00 ± 1076.509 |
| Female: Year 5 | 12503.33 ± 2867.849 |
| Female: Year 6 | 13678.50 ± 603.162 |
| Female: Year 7 | 13446.50 ± 931.260 |
| Female: Year 8 | 11858.00 ± NA |
Genetic analysis was performed to record FGFR3 gene mutation. Genomic DNA was extracted from lymphocytes of collected blood samples using standard procedures. A set of intronic primers was designed based on the genomic sequence of the human FGFR3 gene and used to amplify exons 2-19. Number of subjects with FGFR3 mutation were reported.
| Subjects | r-hGH (Saizen®) |
|---|---|
| Number of Subjects With Fibroblast Growth Factor Receptor (FGFR3) Mutation | 14 |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose.
| Subjects | r-hGH (Saizen®) |
|---|---|
| AEs | 18 |
| SAEs | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| r-hGH (Saizen®) | 0/19 (0%) | 1/19 (5.3%) | 18/19 (94.7%) |
| Event | r-hGH (Saizen®) |
|---|---|
| Abdominal painGastrointestinal disorders | 1/19 |
| AppendicitisInfections and infestations | 1/19 |
| Event | r-hGH (Saizen®) |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/19 |
| Abdominal PainGastrointestinal disorders | 5/19 |
| ScoliosisMusculoskeletal and connective tissue disorders | 5/19 |
| Knee deformityMusculoskeletal and connective tissue disorders | 4/19 |
| HeadacheNervous system disorders | 4/19 |
| PyrexiaGeneral disorders | 3/19 |
| BronchitisInfections and infestations | 3/19 |
| GastroenteritisInfections and infestations | 3/19 |
| Insulin-like growth factor increasedInvestigations | 3/19 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 3/19 |
Intention to Treat (ITT) population included all subjects who received at least one dose of treatment with at least an efficacy assessment available during the treatment period.
| Age, Continuous(Years) | r-hGH (Saizen®) |
|---|---|
| Mean | 9.0 ± 3.12 |
| Sex/Gender, Customized(Participants) | r-hGH (Saizen®) |
|---|---|
| Female | 11 |
| Male | 8 |
Ran from Mar 2006 to primary completion in Jan 2017, 129 months.
Results were first posted in Feb 2019, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →